Secarna Pharmaceuticals GmbH & Co. KG

Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Secarna Pharmaceuticals presents data at SITC demonstrating the potential of antisense oligonucleotides in targeting NRP1

Secarna Pharmaceuticals presents data at OTS showcasing unique characteristics and factors with a role in the activity and side effect profile of LNA-modified ASOs

Secarna Pharmaceuticals to present two posters showcasing the innovation potential of the LNAplus platform at the 19th Annual Meeting of the Oligonucleotide Therapeutic Society

Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases

Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

Secarna Pharmaceuticals and SciNeuro Pharmaceuticals enter into research and option agreement in the field of CNS diseases

First subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide candidate derived from Secarna Pharmaceutical’s LNAplus™ technology platform

Secarna Pharmaceuticals’ strategic partner Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

Secarna Pharmaceuticals’ partner Denali Therapeutics exercises option for LNAplusTM antisense oligonucleotide development program in neurodegeneration

Secarna Pharmaceuticals and Achilles Therapeutics sign research, option and license agreement to develop optimized T cell therapies

Secarna Pharmaceuticals and Denali Therapeutics expand strategic partnership for the discovery and development of novel ASO therapeutics in the field of CNS diseases

Secarna Pharmaceuticals has initiated a transnational scientific consortium to identify new biomarkers for personalized cancer immunotherapy with ASOs

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus(TM)-based ASOs to effectively treat diabetic kidney disease

Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Evotec expand strategic partnership in the field of antisense drug discovery

Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

Secarna Pharmaceuticals appoints Alexander Gebauer, MD, PhD as CEO and Managing Director

Data published in Molecular Diagnostics & Therapy demonstrate how Secarna’s powerful bioinformatics generate improved LNA-modified antisense oligonucleotide therapies

Antisense oligonucleotide candidate derived from Secarna Pharmaceuticals’ LNAplusTM platform has entered pre-clinical safety trials for the treatment of elevated blood lipids

Data published in Cancer Research show Secarna Pharmaceuticals’ LNAplus(TM) ASOs targeting metadherin significantly slow progression and metastasis of colorectal and lung cancers in vivo

Secarna Pharmaceuticals and Denali Therapeutics enter into research and option agreement to develop novel antisense therapies in the field of neurodegenerative diseases

Secarna Pharmaceuticals and Evotec form strategic partnership in the field of antisense therapy

Secarna Pharmaceuticals enters into cooperation with Guangzhou’s Sun Yat-sen University to develop a treatment for SARS-CoV-2 viral infections

Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals’ LNA-modified ASOs to effectively block important immunosuppressive pathway

Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals

Secarna Pharmaceuticals successfully completes financing round

Secarna Pharmaceuticals to Attend International Partnering and Investor Conferences in November

Secarna Pharmaceuticals enters into oncology research agreement with global top 10 pharmaceutical company

Publications of Secarna Pharmaceuticals’ immuno-oncology data in peer-reviewed scientific journals support potential of LNAplusTM antisense oligonucleotide platform for discovering novel cancer therapies

Secarna Pharmaceuticals and MetP Pharma enter into a co-development agreement for transnasally delivered antisense oligonucleotide-based CNS therapeutics